A Safety and Efficacy Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00528697 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

278

Enrollment

INDUSTRY

Sponsor class

Conditions

Attention-Deficit/Hyperactivity Disorder

Interventions

DRUG: ABT-089
DRUG: atomoxetine
DRUG: placebo

Sponsor

AbbVie (prior sponsor, Abbott)